Article

Retinoid shows promise

The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has given an oral synthetic retinoid (QLT091001, QLT Inc.) positive opinions for two distinct orphan drug designations for the treatment of the inherited retinal degenerative diseases, Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP), according to the company.

Vancouver, BC-The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has given an oral synthetic retinoid (QLT091001, QLT Inc.) positive opinions for two distinct orphan drug designations for the treatment of the inherited retinal degenerative diseases, Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP), according to the company.

The action comes on the heels of the retinoid being designated an orphan drug by the FDA for the treatment of LRAT and RPE65 genetic mutations in both LCA and RP. The orally administered synthetic retinoid replacement for 11-cis-retinal, a key biochemical component of the visual retinoid cycle, is under investigation for the treatment of LCA and RP.

“We are pleased that the EMA has recognized [the retinoid] as a potential treatment for the thousands of patients who suffer from inherited blindness by granting positive opinions for these orphan drug designations for the treatment of LCA and RP,” said Bob Butchofsky, president and chief executive officer of QLT. “These are critical steps in our development and regulatory plans, and we will continue to work diligently to develop this potential treatment, and look forward to working with the EMA closely as this program moves forward.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.